|
Fibrosis
|
0.500 |
Biomarker
|
phenotype |
RGD |
[The antagonistic effect of PI3K-gamma inhibitor AS605240 on cardiac hypertrophy and cardiac fibrosis induced by isoproterenol in rats].
|
21866628 |
2011 |
|
Fibrosis
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
Our data show that PI3Kgamma is critical for the induction of hypertrophy, fibrosis, and cardiac dysfunction function in response to beta-adrenergic receptor stimulation in vivo.
|
12963636 |
2003 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this review, we focus on the cardioprotective properties of APC in ischemic heart disease and heart failure with a special emphasis on recent discoveries related to the modulatory effect of APC on AMP-activated protein kinase (AMPK), PI3K/AKT, and mTORC1 signaling pathways.
|
30974752 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The protective effect of kaempferol on heart via the regulation of Nrf2, NF-κβ, and PI3K/Akt/GSK-3β signaling pathways in isoproterenol-induced heart failure in diabetic rats.
|
30864233 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The protective effect of kaempferol on heart via the regulation of Nrf2, NF-κβ, and PI3K/Akt/GSK-3β signaling pathways in isoproterenol-induced heart failure in diabetic rats.
|
30864233 |
2019 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this review, we focus on the cardioprotective properties of APC in ischemic heart disease and heart failure with a special emphasis on recent discoveries related to the modulatory effect of APC on AMP-activated protein kinase (AMPK), PI3K/AKT, and mTORC1 signaling pathways.
|
30974752 |
2019 |
|
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, these findings highlight a key role for PI3K/mTOR signalling in GLI1 regulation in HH-driven cancers and suggest that combined PI3Kα/mTOR inhibition may be particularly interesting for the development of effective treatment strategies in high-risk medulloblastomas.
|
31492956 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A PI3K inhibitor with predominant α/δ activity, copanlisib, exhibited the highest cytotoxicity in all BCR-dependent DLBCLs.
|
30322870 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We analyzed cancer-specific biclusters and found that the PI3K/Akt signaling pathway is strongly enriched with targets of a few miRNAs in breast cancer and diffuse large B-cell lymphoma.
|
30820547 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas.
|
31471373 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phosphatidylinositol-3 kinase (PI3K) signaling is a common feature of B-cell neoplasms, including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL), and PI3K inhibitors have been introduced into the clinic.
|
31831562 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The phosphatidylinositol 3-kinase (PI3K)/RAC-α serine/threonine-protein kinase (AKT) pathway is constitutively activated in a number of lymphoid malignancy types, including diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma.
|
30881494 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, our results suggest that ROR1 is a novel prognostic marker for DLBCL survival and ROR1 significantly promotes DLBCL tumorigenesis by regulating the PI3K/Akt/mTOR signaling pathway.
|
30801854 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results of Bioinformatics analysis revealed that the target genes including NEDD4L and UBA52 and several associated pathways including PI3K/AKT and MAPK/ERK might be involved in the development of CD5+ R/R DLBCL.
|
31775867 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ginsenoside Rb1 inhibits autophagy through regulation of Rho/ROCK and PI3K/mTOR pathways in a pressure-overload heart failure rat model.
|
29574918 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ginsenoside Rb1 inhibits autophagy through regulation of Rho/ROCK and PI3K/mTOR pathways in a pressure-overload heart failure rat model.
|
29574918 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ulinastatin induced the activation of the phosphatidylinositol 3‑kinase (PI3K)/RAC‑α serine/threonine protein kinase (Akt) signaling pathway and downregulated the p38 mitogen‑activated protein kinase (MAPK) and nuclear factor (NF)‑κB pathway in isoproterenol‑induced CHF rats.
|
29115471 |
2018 |
|
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The data from the present study suggest that TRIM59 induces epithelial-to-mesenchymal transition and promotes migration and invasion by PI3K/AKT signaling pathway in medulloblastoma.
|
29805559 |
2018 |
|
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, we investigated the anti-MB efficacies of combined HH inhibitor Vismodegib and PI3K-mTOR dual-inhibitor BEZ235 together or combined individually with cisplatin against high-risk MB.
|
29682173 |
2018 |
|
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that LncRNA LOXL1-AS1 promoted the proliferation and metastasis of medulloblastoma by activating the PI3K-AKT pathway, providing evidence that knockdown of LncRNA LOXL1-AS1 might be a potential therapeutic strategy against medulloblastoma.
|
30050750 |
2018 |
|
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this context, we demonstrate that the clinically available PI3K inhibitor GDC-0941 enhances the anti-neoplastic efficacy of Axitinib against c-myc-amplified medulloblastoma.
|
29377550 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In a high-throughput combinatorial drug screening experiment, BETi enhance the antiproliferative effects of PI3K inhibitors in a panel of diffuse large B cell lymphoma (DLBCL) and Burkitt lymphoma cell lines.
|
30134175 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Transient antagonism of anti-CD20 monoclonal antibodies and PI3K inhibitor idelalisib in DLBCL cell lines.
|
29617050 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Constitutive activation of IGF-1R, MEK, or PI3K pathways was sufficient to confer resistance to EZH2 inhibitors in DLBCL.
|
29572378 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we examined the mechanism by which the cyclic-AMP/PDE4 signaling axis suppresses PI3K, toward identifying a novel mechanism-based combinatorial strategy to attack BCR-dependency in mature B-cell malignancies.<b>Experimental Design:</b> We used <i>in vitro</i> and <i>in vivo</i> diffuse large B-cell lymphoma (DLBCL) cell lines and primary chronic lymphocytic leukemia (CLL) samples to preclinically evaluate the effects of the combination of the FDA-approved phosphodiesterase 4 (PDE4) inhibitor roflumilast and idelalisib on cell survival and tumor growth.
|
29246942 |
2018 |